Samjin Pharmaceuticals (A005500) Stock Overview
Manufactures and sells medicine. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 1/6 |
A005500 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Samjin Pharmaceuticals Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩20,350.00 |
| 52 Week High | ₩25,900.00 |
| 52 Week Low | ₩16,990.00 |
| Beta | 0 |
| 1 Month Change | 8.77% |
| 3 Month Change | 7.79% |
| 1 Year Change | 12.74% |
| 3 Year Change | -9.96% |
| 5 Year Change | -25.59% |
| Change since IPO | 606.85% |
Recent News & Updates
Recent updates
Shareholder Returns
| A005500 | KR Pharmaceuticals | KR Market | |
|---|---|---|---|
| 7D | -9.2% | -4.7% | 6.7% |
| 1Y | 12.7% | 17.3% | 195.0% |
Return vs Industry: A005500 underperformed the KR Pharmaceuticals industry which returned 17.3% over the past year.
Return vs Market: A005500 underperformed the KR Market which returned 195% over the past year.
Price Volatility
| A005500 volatility | |
|---|---|
| A005500 Average Weekly Movement | 13.4% |
| Pharmaceuticals Industry Average Movement | 7.3% |
| Market Average Movement | 9.5% |
| 10% most volatile stocks in KR Market | 16.6% |
| 10% least volatile stocks in KR Market | 4.9% |
Stable Share Price: A005500's share price has been volatile over the past 3 months compared to the KR market.
Volatility Over Time: A005500's weekly volatility has increased from 7% to 13% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1968 | n/a | Kyu Cho | www.samjinpharm.co.kr |
Samjin Pharmaceuticals Co., Ltd. manufactures and sells medicine. It offers medicine in oral, drop, and injecting forms. The company provides over-the-counter medicines, such as Gevorin, an anti-infalammatory pain killer; Trestan, an appetite stimulant; Flaris, an anti-thrombotic agent; and Nutilin, a brain function improvement agent, as well as medicine for treatment of chronic diseases.
Samjin Pharmaceuticals Co., Ltd. Fundamentals Summary
| A005500 fundamental statistics | |
|---|---|
| Market cap | ₩249.45b |
| Earnings (TTM) | ₩21.89b |
| Revenue (TTM) | ₩274.03b |
Is A005500 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A005500 income statement (TTM) | |
|---|---|
| Revenue | ₩274.03b |
| Cost of Revenue | ₩156.30b |
| Gross Profit | ₩117.73b |
| Other Expenses | ₩95.84b |
| Earnings | ₩21.89b |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did A005500 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/31 03:36 |
| End of Day Share Price | 2026/05/29 00:00 |
| Earnings | 2022/12/31 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Samjin Pharmaceuticals Co., Ltd. is covered by 7 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Hyuk Jin Yoon | Eugene Investment & Securities Co Ltd. |
| Jae Hoon Shin | Hanwha Investment & Securities Co., Ltd. |
| Jong Kyung Choi | Heungkuk Securities Co., Ltd |